NCT03386526: APG-1387 in Patients With Advanced Solid Tumors or Hematologic Malignancies

NCT03386526
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Misc Inhibitor

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Senior)
Location of Metastases: 
Additional Notes: 
Exclusions: Known active central nervous (CNS) metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03386526

Comments are closed.

Up ↑